These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 32296096)

  • 1. Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital.
    Chung SJ; Lee H; Koo GW; Min JH; Yeo Y; Park DW; Park TS; Moon JY; Kim SH; Kim TH; Sohn JW; Yoon HJ
    Sci Rep; 2020 Apr; 10(1):6462. PubMed ID: 32296096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
    Simkins J; Abbo LM; Camargo JF; Rosa R; Morris MI
    Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of latent tuberculous infection among health care workers at a tertiary hospital in Korea.
    Lee EH; Kim SJ; Ha EJ; Park ES; Choi JY; Leem AY; Kim SY; Park MS; Kim YS; Kang YA
    Int J Tuberc Lung Dis; 2018 Nov; 22(11):1336-1343. PubMed ID: 30355414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse event and treatment completion rates of a 12-dose weekly isoniazid and rifapentine course for South Korean healthcare workers.
    Jo KW; Kim JS; Kwon HS; Park YE; Kim JY; Hong MJ; Shim TS
    Respir Med; 2019; 158():42-48. PubMed ID: 31605920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation and treatment of latent tuberculosis infection among healthcare workers in Korea: A multicentre cohort analysis.
    Han SS; Lee SJ; Yim JJ; Song JH; Lee EH; Kang YA
    PLoS One; 2019; 14(9):e0222810. PubMed ID: 31536577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
    Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
    Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
    Bliven-Sizemore EE; Sterling TR; Shang N; Benator D; Schwartzman K; Reves R; Drobeniuc J; Bock N; Villarino ME;
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1039-44, i-v. PubMed ID: 26260821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective cohort study of latent tuberculosis in adult close contacts of active pulmonary tuberculosis patients in Korea.
    Park SH; Lee SJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Kim HJ; Menzies D
    Korean J Intern Med; 2016 May; 31(3):517-24. PubMed ID: 27052266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center.
    Arguello Perez E; Seo SK; Schneider WJ; Eisenstein C; Brown AE
    Clin Infect Dis; 2017 Nov; 65(12):2105-2111. PubMed ID: 29020308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with non-initiation of latent tuberculosis treatment among healthcare workers with a positive interferon-gamma releasing assay.
    Lee H; Koo GW; Min JH; Park TS; Park DW; Moon JY; Kim SH; Kim TH; Yoon HJ; Sohn JW
    Sci Rep; 2019 Jan; 9(1):61. PubMed ID: 30635600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
    Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
    Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
    Gray EL; Goldberg HF
    Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs.
    Ronald LA; FitzGerald JM; Bartlett-Esquilant G; Schwartzman K; Benedetti A; Boivin JF; Menzies D
    Eur Respir J; 2020 Mar; 55(3):. PubMed ID: 31980498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population.
    Jiménez-Fuentes MA; de Souza-Galvao ML; Mila Augé C; Solsona Peiró J; Altet-Gómez MN
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):326-32. PubMed ID: 23407221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older.
    Noh CS; Kim HI; Choi H; Kim Y; Kim CH; Choi JH; Hyun IG; Baek MS
    Respir Med; 2019 Oct; 157():52-58. PubMed ID: 31522030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study.
    Chang AH; Polesky A; Bhatia G
    BMC Public Health; 2013 Sep; 13():894. PubMed ID: 24073620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
    Fresard I; Bridevaux PO; Rochat T; Janssens JP
    Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compliance with postexposure screening and treatment of latent tuberculosis infection among healthcare workers in a tertiary care hospital in Saudi Arabia.
    Balkhy HH; Miller TL; Ali S; Nuzzo JB; Kentenyants K; El-Saed A; McNabb SJ
    Infect Control Hosp Epidemiol; 2014 Feb; 35(2):176-81. PubMed ID: 24442081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.
    Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Barbeau P; Skidmore B; Alvarez GG
    Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):557-566. PubMed ID: 29573031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
    Tseng SY; Huang YS; Chang TE; Perng CL; Huang YH
    J Chin Med Assoc; 2021 Nov; 84(11):993-1000. PubMed ID: 34747900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.